BIOVOX

About BIOVOX

BIOVOX is a German company founded in 2021 that develops and produces sustainable, medical-grade bioplastic compounds for the healthcare, pharmaceutical, and laboratory sectors. The company aims to address the significant carbon footprint of the healthcare industry, where single-use plastics are prevalent. BIOVOX's materials are designed to be a safe, recyclable, and bio-based alternative to conventional fossil-based plastics, reducing CO2 emissions by up to 85%.

The company was founded by Dr. Julian Lotz (CEO), Carmen Rommel (COO), and Dr. Vinzenz Nienhaus (CTO), all of whom are mechanical engineers from the Technical University of Darmstadt. Their collective background in plastics technology, sustainable product development, and medical technology spurred the idea to tackle plastic waste in clinical settings. The initial concept emerged around 2018, leading to the official founding in late 2020. In September 2024, BIOVOX successfully closed a €2.2 million seed funding round led by High-Tech Gründerfonds (HTGF) to scale operations and establish a proprietary technical center.

BIOVOX operates on a B2B model, selling its specialized MedEco thermoplastic granules to medical device manufacturers. These materials are compliant with medical industry standards, including ISO 13485, and are tested for biocompatibility according to ISO 10993. The product portfolio includes materials with a range of properties, such as rigidity or softness, transparency, and suitability for various manufacturing processes like injection molding and 3D printing. Applications for their bioplastics include surgical instruments, disposables, packaging, and drug delivery devices. By offering a sustainable and regulatory-compliant material, BIOVOX enables its clients, which number over 50, to develop products for a circular economy without compromising on patient safety or performance.